Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model

Beatty GL, Paterson Y (2000) IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J Immunol 165(10):5502–5508

Binder RJ (2008) Heat-shock protein-based vaccines for cancer and infectious disease. Expert Rev Vaccine 7:383–393

Block MS, Markovic SN (2009) The tumor/immune interface: clinical evidence of cancer immunosurveillance, immunoediting and immunosubversion. Am J Immunol 5(1):29–49

Cappello P, Triebel F, Iezzi M, Caorsi C, Quaglino E, Lollini PL et al (2003) LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res 63:2518–2525

Chang SY, Lee KC, Ko SY, Ko HJ, Kang CY (2004) Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Int J Cancer 111:86–95

Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC (1994) Green fluorescent protein as a marker for gene expression. Science 263:802–805

Dela Cruz JS, Morrison SL, Penichet ML (2005) Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein. Vaccine 23:4793–4803

Disis ML, Scholler N, Dahlin A, Pullman J, Knutson KL, Hellström KE et al (2003) Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity. Mol Cancer Ther 2:995–1002

Facciponte JG, Wang XY, MacDonald IJ, Park JE, Arnouk H, Grimm MJ et al (2006) Heat shock proteins HSP70 and GP96: structural insights. Cancer Immunol Immunother 55(3):339–346

He YF, Wang XH, Zhang GM, Chen HT, Zhang H, Feng ZH (2005) Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol Immunother 54(9):891–897

Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95(13):7556–7561

Kmieciak M, Knutson KL, Dumur CI, Manjili MH (2007) HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol 37:675–685

Lepique AP, Regina K, Daghastanli P, Cuccovia IM, Villa LL (2009) HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res 15:4391–4400

Li H, Zhou M, Han J, Zhu X, Dong T, Gao GF et al (2005a) Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J Immunol 174:195–204

Li HT, Yan JB, Li J, Zhou MH, Zhu XD, Zhang YX et al (2005b) Enhancement of humoral immune responses to HBsAg by heat shock protein gp96 and its N-terminal fragment in mice. World J Gastroenterol 11:2858–2863

Lin CC, Chou CW, Shiau AL, Tu CF, Ko TM, Chen YL et al (2004) Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu. Mol Ther 10:290–301

Liu K, Caldwell SA, Abrams SI (2005) Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression. Cancer Res 65(10):4376–4388

Manjili MH, Kmieciak M (2008) Does HER-2/neu antigen loss in metastatic breast tumors occur under immune pressure? Int J Cancer 123(6):1476–1477

Marth C, Mueller-Holzner E, Greiter E, Cronauer MV, Zeimet AG, Doppler W et al (1990) Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells. Cancer Res 50:7037–7041

Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K et al (1997) Peptides derived from a wild-type murine protooncogene c-erbB-2/HER2/2 neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 159:1336–1343

Nagaraj S, Gabrilovich DI (2008) Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 68:2561–2563

Nicchitta CV (2003) Re-evaluating the role of heat-shock protein peptide interactions in tumour immunity. Nat Rev Immunol 3:427–432

Nicchitta CV, Carrick DM, Baker-Lepain JC (2004) The messenger and the message: gp96 (GRP94)–peptide interactions in cellular immunity. Cell Stress Chaperones 9(4):325–331

Nishikawa H, Kato T, Tawara I, Ikeda H, Kuribayashi K, Allen PM et al (2005) IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. J Immunol 175(7):4433–4440

Orlandi F, Venanzi FM, Concetti A, Yamauchi H, Tiwari S, Norton L et al (2007) Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine. Clin Cancer Res 13:6195–6203

Pakravan N, Soudi S, Hassan ZM (2010b) N-terminally fusion of Her2/neu to HSP70 decreases efficiency of Her2/neu DNA vaccine. Cell Stress Chaperones 15:631–638

Pakravan N, Langroudi L, Hajimoradi M, Hassan ZM (2010c) Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model. Cell Stress Chaperones 15(6):977–984

Quaglino E, Mastini C, Iezzi M, Forni G, Musiani P, Klapper LN et al (2005) The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice. Vaccine 23:3280–3287

Rapp UK, Kaufmann SH (2004) DNA vaccination with gp96–peptide fusion proteins induces protection against an intracellular bacterial pathogen. Int Immunol 16:597–605

Rovero S, Amici A, Carlo ED, Bei R, Nanni P, Quaglino E et al (2000) DNA vaccination against rat Her-2/neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165(9):5133–5142

Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, Hurwitz AA (2009) Cutting edge: tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol 183:4848–4852

Shevach EM (2006) From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25:195–201

Spadaro M, Ambrosino E, Iezzi M, Di Carlo E, Sacchetti P, Curcio C et al (2005) Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res 11:1941–1952

Spoelstra FM, Postma DS, Hovenga H, Noordhoek JA, Kauffman HF (1999) Interferon-gamma and interleukin-4 differentially regulate ICAM-1 and VCAM-1 expression on human lung fibroblasts. Eur Respir J 14:759–766

Srivastava P (2002) Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20:395–425

Thornhill MH, Wellicome SM, Mahiouz DL, Lanchbury JS, Kyan-Aung U, Haskard DO (1991) Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding. J Immunol 146:592–598

Wang Y, Liu D, Chen P, Koeffler HP, Tong X, Xie D (2008) Negative feedback regulation of IFN-gamma pathway by IFN regulatory factor 2 in esophageal cancers. Cancer Res 68:1136–1143

Wei WZ, Shi WP, Galy A, Lichlyter D, Hernandez S, Groner B et al (1999) Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 81:748–754

Worschech A, Kmieciak M, Knutson KL, Bear HD, Szalay AA, Wang E et al (2008) Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res 68:2436–2446

Yan J, Liu X, Wang Y, Jiang X, Liu H, Wang M et al (2007) Enhancing the potency of HBV DNA vaccines using fusion genes of HBV-specific antigens and the N-terminal fragment of gp96. J Gene Med 9:107–121